SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively position for the pending 80th event trigger in its REGAL Phase 3 trial, a key milestone that could unblind survival data and ignite M&A interest from major pharmaceutical players. Community sentiment is polarized between long-term investors tracking clinical math and active short sellers struggling with rising borrow costs and high margin requirements as the market awaits definitive topline results.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant community attention as investors position themselves for upcoming Ethereum mainnet integration and potential regulatory catalysts that could drive institutional liquidity into the Base ecosystem. While traders are actively debating price floors and accumulation strategies, discussion is heavily focused on the protocol's sustained revenue generation compared to other decentralized exchanges.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following an earnings report that showcased robust revenue growth and an optimistic outlook, fueling significant retail and institutional interest. Community sentiment is deeply divided between long-term investors highlighting the stock's pivot into AI-powered semiconductor technology and skeptics cautioning that the current rally may invite a share offering or a classic post-hype retracement.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to rising investor focus on its upcoming earnings report and the broader implications of its Valaris merger in a constrained offshore drilling market. The community is actively debating the stock's valuation and debt reduction progress against a backdrop of geopolitical tensions in the Middle East that continue to affect global energy supplies.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense volatility, fueled by active community debates over potential short squeezes and speculation regarding whale accumulation versus ongoing pump-and-dump concerns. Investors are closely monitoring volume patterns and price support levels, often comparing current market behavior to previous rapid run-ups in the token.

TOSHI

TOSHI is trending as investors highlight its status as a major Base network asset and discuss recent AI-driven utility integrations. The community is actively debating the project's long-term potential, focusing on buyback and lock mechanisms while expressing both frustration with recent price action and optimism for a future rally.

Chip

Community sentiment remains polarized as traders debate whether the project is a legitimate infrastructure play for GPU-backed financing or a volatile asset prone to insider selling. Investors are closely monitoring volume spikes and protocol activity as they look for catalysts to break through recent technical resistance levels.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community debate over a potential buyout versus the risks of independent commercialization, as investors look ahead to upcoming Phase 1 maintenance trial results. While some shareholders are frustrated by the stock's recent performance relative to the broader biotech sector, others remain focused on the company's strong pipeline and the long-term potential of its GLP-1 assets to disrupt the obesity market.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing significant market interest and institutional attention due to its official inclusion in the Nasdaq-100 index, a move that mandates buying by index-tracking funds. The community is actively debating the company's valuation relative to its massive contract backlog and AI infrastructure buildout, while contrasting its growth trajectory with sector peers amid ongoing discussions about insider selling and debt levels.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors anticipate the upcoming Phase 3 trial launch for its NSCLC program, which many believe will shift market perception from a single-asset company to a multi-indication oncology platform. Community sentiment remains highly bullish, with significant discussion focused on the stock's low valuation relative to its clinical progress, the tightness of the float, and the high potential for a lucrative partnership or buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Purple Biotech CEO Gil Efron To Step Down For Health Reasons

(RTTNews) - Purple Biotech Ltd. (PPBT), a clinical-stage pharmaceutical company, Friday announced that its Chief Executive Officer, Gil Efron will step down from his role in August, due to health...

Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug

Equity

Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech Ltd - ADR

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

PPBTPurple Biotech Ltd - ADR

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest PPBT News